Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: JACC Heart Fail. 2019 Mar;7(3):228–238. doi: 10.1016/j.jchf.2019.01.003

Figure 2b – Kaplan-Meier survival curves for secondary outcomes according to treatment arm and stratified by sex.

Figure 2b –

Spironolactone was associated with a significantly reduced likelihood of all-cause mortality with a significant sex-treatment arm interaction. There was no association between spironolactone and likelihood of non-CV mortality, CV hospitalization, or non-CV hospitalization.